Status:
ACTIVE_NOT_RECRUITING
Dexmedetomidine and Myocardial Protection
Lead Sponsor:
Seoul National University Hospital
Conditions:
Cardiac Surgery
Cardiopulmonary Bypass
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Dexmedetomidine, an alpha-2 agonist, is a sedative that is widely used in various clinical settings because, compared to benzodiazepines, it preserves respiratory function better and its duration of a...
Eligibility Criteria
Inclusion
- cardiac surgery utilizing cardiopulmonary bypass and aortic cross-clamp
Exclusion
- Coronary artery bypass grafting
- Concomitant cryo-Maze procedure
- Myectomy
- Heart transplantation
- Concomitant major non-cardiac surgery
- Isolated complicated congenital heart surgery
- descending thoracic aorta surgery with partial cardiopulmonary bypass
- Emergency surgery
- Minimally invasive or robot-assisted surgery
- Estimated GFR \<30 ml/min/1.73 m2
- Documented end-stage renal disease
- Preoperative renal replacement therapy
- Preoperative history of percutaneous coronary intervention within 6 month before surgery
- Acute coronary syndrome within 4 weeks before surgery
- Preoperative mechanical circulatory support devices
Key Trial Info
Start Date :
July 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04871308
Start Date
July 7 2021
End Date
December 30 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080